Steven Gilman of Contrafect Corporation: Featured Speaker of World Anti-Microbial Resistance Congress

Steven Gilman of Contrafect Corporation: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist in 2008, Dr. Gilman served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation franchise, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization. Prior to Millennium, he was Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College.

Dr. Gilman currently serves on the board of directors of publicly traded companies Keryx Biopharmaceuticals, Inc., SCYNEXIS Inc, and Vericel Corporation, the Massachusetts Biotechnology Association and the Penn State University Biotechnology Advisory Board.

Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio. He has authored over 60 publications and is an inventor on 7 patents.

Dr. Gilman will be speaking at World Anti-Microbial Resistance Congress USA 2016 about ‘Lysins as narrow spectrum anti infectives for the treatment of serious drug resistant bacterial infections’. This session will cover using bacteriophage enzymes to cleave the bacterial cell wall, clear biofilms and prevent resistance as well as how lysins can be used synergistically with standard of care antibiotics and current data and future development plans. To hear from Dr. Gilman and more industry experts, attend World Anti-Microbial Resistance Congress USA 2016 held September 8-9 in Washington, DC.

Attend World Anti-Microbial Resistance USA 2016

Leave a Reply

Your email address will not be published. Required fields are marked *